Jan 24, 2020   SOURCE: PR NewsWire

Obsessive-Compulsive Disorder Therapeutic Landscape & Pipeline Review (2020, H1)

DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The "Obsessive-Compulsive Disorder - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

The Pharmaceutical and Healthcare latest pipeline guide

Obsessive-Compulsive Disorder - Pipeline Review, H1 2020

, provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape of Obsessive-Compulsive Disorder (Central Nervous System).
    --  The pipeline guide reviews pipeline therapeutics for
        Obsessive-Compulsive Disorder (Central Nervous System) by companies and
        universities/research institutes based on information derived from
        company and industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
        stages.
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in
        Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and
        enlists all their major and minor projects.
    --  The pipeline guide evaluates Obsessive-Compulsive Disorder (Central
        Nervous System) therapeutics based on mechanism of action (MoA), drug
        target, route of administration (RoA) and molecule type.
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.
    --  The pipeline guide reviews latest news related to pipeline therapeutics
        for Obsessive-Compulsive Disorder (Central Nervous System).

Reasons to Buy

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Obsessive-Compulsive Disorder (Central Nervous System).
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
        companies.
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding
        Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth
        and focus of Indication therapeutics.
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.

Key Topics Covered

    1. Introduction
    2. Report Coverage
    3. Obsessive-Compulsive Disorder - Overview
    4. Obsessive-Compulsive Disorder - Therapeutics Development
    5. Pipeline Overview
    6. Pipeline by Companies
    7. Pipeline by Universities/Institutes
    8. Products under Development by Companies
    9. Products under Development by Universities/Institutes
    10. Obsessive-Compulsive Disorder - Therapeutics Assessment
    11. Assessment by Target
    12. Assessment by Mechanism of Action
    13. Assessment by Route of Administration
    14. Assessment by Molecule Type

Featured News & Press Releases

    --  Sep 16, 2019: Omeros announces positive results from phase 1 study of
        its lead PDE7 inhibitor in development for addiction
    --  Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In
        Addiction

Companies Mentioned 

    --  Addex Therapeutics Ltd.
    --  Amorsa Therapeutics Inc.
    --  Biogen Inc.
    --  Biohaven Pharmaceutical Holding Company Ltd.
    --  Cannabis Science Inc.
    --  Omeros Corp.
    --  Phytecs
    --  Rugen Therapeutics R&D (Shanghai) Co. Ltd.
    --  Seropeutics LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8d3onl

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/obsessive-compulsive-disorder-therapeutic-landscape--pipeline-review-2020-h1-300992824.html

SOURCE Research and Markets